Downregulation of the male-specific hepatic microsomal steroid 16 alpha-hydroxylase, cytochrome P-450UT-A, in rats with portal bypass. Relevance to estradiol accumulation and impaired drug metabolism in hepatic cirrhosis
- PMID: 2703529
- PMCID: PMC303809
- DOI: 10.1172/JCI114003
Downregulation of the male-specific hepatic microsomal steroid 16 alpha-hydroxylase, cytochrome P-450UT-A, in rats with portal bypass. Relevance to estradiol accumulation and impaired drug metabolism in hepatic cirrhosis
Abstract
Elevated serum estradiol concentrations and specific changes in the biliary excretion of some androstenedione metabolites have been reported in male rats with portal bypass produced by portal vein ligation (PVL). In this study, the hypothesis that male-specific forms of cytochrome P-450 are altered after PVL was tested by measuring microsomal steroid hydroxylase activities. Consistent with earlier findings in the intact animal, androstenedione 16 alpha-hydroxylase activity was reduced after PVL to 44% of control (P less than 0.05). Other pathways of androstenedione hydroxylation, and total estrogen formation (after androstenedione aromatization) were unchanged. Although total estrogen formation was not different, a sevenfold greater proportion of estradiol was produced in PVL rat microsomes. Additional experiments revealed that PVL selectively reduced the rate of microsomal estradiol 16 alpha-hydroxylation (to 56% of control, P less than 0.02). Levels of cytochrome P-450UT-A, the microsomal steroid 16 alpha-hydroxylase, were lower after PVL (56% of control, P less than 0.05), so that the present observations are consistent with the earlier suggestion that portal bypass is associated with the selective downregulation of this enzyme. Since downregulation of cytochrome P-450UT-A also occurs in experimental hepatic cirrhosis, portal hypertension may well contribute significantly to altered drug metabolism in liver disease. Impaired hepatic elimination of androstenedione by hydroxylation may indirectly enhance extrahepatic aromatization of the androgen. The decreased activity of hepatic estradiol 16 alpha-hydroxylation after PVL would enhance the accumulation of estradiol, the biologically more potent estrogen.
Similar articles
-
Altered regulation of cytochrome P-450 enzymes in choline-deficient cirrhotic male rat liver: impaired regulation and activity of the male-specific androst-4-ene-3,17-dione 16 alpha-hydroxylase, cytochrome P-450UT-A, in hepatic cirrhosis.Mol Pharmacol. 1987 Jan;31(1):117-21. Mol Pharmacol. 1987. PMID: 3543647
-
Impaired androgen 16 alpha-hydroxylation in hepatic microsomes from carbon tetrachloride-cirrhotic male rats.Gastroenterology. 1987 Jul;93(1):141-7. doi: 10.1016/0016-5085(87)90326-x. Gastroenterology. 1987. PMID: 3582901
-
Source of raised serum estrogens in male rats with portal bypass.J Clin Invest. 1988 Jan;81(1):221-8. doi: 10.1172/JCI113299. J Clin Invest. 1988. PMID: 3335638 Free PMC article.
-
In vitro cytochrome P450-mediated hepatic activities for five substrates in specific pathogen free chickens.J Vet Pharmacol Ther. 2001 Oct;24(5):343-8. doi: 10.1046/j.1365-2885.2001.00349.x. J Vet Pharmacol Ther. 2001. PMID: 11696084 Review.
-
[Physiological, genetic and pathological factors regulating the reductive metabolism of drugs with a ketone group].Yakugaku Zasshi. 1999 Nov;119(11):835-49. doi: 10.1248/yakushi1947.119.11_835. Yakugaku Zasshi. 1999. PMID: 10590711 Review. Japanese.
Cited by
-
P450 enzymes. Inhibition mechanisms, genetic regulation and effects of liver disease.Clin Pharmacokinet. 1992 Aug;23(2):132-46. doi: 10.2165/00003088-199223020-00005. Clin Pharmacokinet. 1992. PMID: 1511529 Review.
-
The ixabepilone and vandetanib combination shows synergistic activity in docetaxel-resistant MDA-MB-231 breast cancer cells.Pharmacol Rep. 2022 Oct;74(5):998-1010. doi: 10.1007/s43440-022-00396-7. Epub 2022 Jul 30. Pharmacol Rep. 2022. PMID: 35908023 Free PMC article.
-
The Role of CYPs and Transporters in the Biotransformation and Transport of the Anti-hepatitis C Antiviral Agents Asunaprevir, Daclatasvir, and Beclabuvir: Impact of Liver Disease, Race and Drug-drug Interactions on Safety and Efficacy.Curr Drug Metab. 2024;25(2):96-109. doi: 10.2174/0113892002288832240213095622. Curr Drug Metab. 2024. PMID: 38441017 Review.
-
Clinical pharmacokinetics in patients with liver disease.Clin Pharmacokinet. 1991 Jul;21(1):42-69. doi: 10.2165/00003088-199121010-00004. Clin Pharmacokinet. 1991. PMID: 1914341 Review.
-
Inhibition of Hepatic CYP2D6 by the Active N-Oxide Metabolite of Sorafenib.AAPS J. 2019 Oct 21;21(6):107. doi: 10.1208/s12248-019-0374-2. AAPS J. 2019. PMID: 31637538
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources